Gainers Recap: Teradyne, Sarepta Therapeutics Inc (NASDAQ:SRPT), Cemex SAB De CV (ADR) (NYSE:CX),

Lakeway, NY -- (SBWIRE) -- 03/05/2013 -- ThePennyStockProfiler.com, an investment community with a special focus on updating investors with recent news on the U.S. stock market, issues news alert on the following stocks:-

Teradyne, Inc. (NYSE:TER) shares climbed 3.05% to $17.25 in the early hour after HP announced that Teradyne has selected HP FlexNetwork architecture to improve operational efficiency, reduce network downtime and boost design-phase efficiency for new products. Teradyne designs and manufactures automatic test equipment for the world's leading electronics companies.

Is TER a Strong Buy After The Recent Gain? Let’s Find out Here

Sarepta Therapeutics Inc (NASDAQ:SRPT) shares gained 1.73% to $30.59. The company will report fourth quarter and full-year 2012 financial results before the NASDAQ Global Market opens on Thursday, March 7, 2013. Subsequently, at 8:00 a.m., Eastern Time (5:00 a.m., Pacific Time), Chris Garabedian, Sarepta's President and CEO, will host a conference call to discuss fourth quarter and full-year financial results and to provide a corporate update.

Additionally, the company yesterday announced positive results from a non-human primate study of AVI-7288, the Company's lead drug candidate for the treatment of Marburg virus infection. The data showed that intramuscular administration of AVI-7288 resulted in survival rates up to 100 percent in treated subjects, similar to efficacy observed in previous studies that evaluated the drug when administered by intravenous injection.

Is SRPT a Strong Buying Opportunity After The Recent Slump? Find out Here

Cemex SAB de CV (ADR) (NYSE:CX) shares gained 3.88% to $11.52. The company, on Feb. 7, announced that for the full year 2012, operating EBITDA increased by 10% to US$2.6 billion, with net sales reaching US$15.0 billion a decline of 2% on a year-over-year basis. During the fourth quarter, operating EBITDA increased by 13% to US$611 million while net sales were stable at US$3.7 billion.

Should Investors Consider CX After The Recent price Action? Get Free Trend Analysis Here

About ThePennyStockProfiler.com
ThePennyStockProfiler.com is engaged in providing the most up to date and useful information on Microcap Stocks poised to breakout. ThePennyStockProfiler.com also provides investors with trend analysis, detailed company profiles, and most importantly a much needed "informational edge" which can be used as a tool for making investment decisions. To Receive Instant updates in the inbox, readers are advised to sign up for free at http://www.ThePennyStockProfiler.com

Disclaimer
The assembled information disseminated by ThePennyStockProfiler.com is for information purposes only, and is neither a solicitation to buy nor an offer to sell securities. ThePennyStockProfiler.com does expect that investors will buy and sell securities based on information assembled and presented in phd-trading.com. PLEASE always do your own due diligence, and consult your financial advisor.